---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-25-000008"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2025-01-21T23:59:59+00:00"
generated_at: "2026-05-27T22:13:48.880876+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Keros-Takeda license for elritercept effective; $200M upfront payment triggered

## Summary
- Global license agreement with Takeda (TSE:4502/NYSE:TAK) for elritercept became effective Jan 16, 2025.
- Upfront payment of $200.0 million from Takeda to Keros was triggered upon effectiveness.
- Agreement was previously announced on Dec 3, 2024; effectiveness followed HSR waiting period expiration.
- Elritercept is a clinical-stage therapy targeting TGF-ß family signaling disorders.

## SEC filing metadata
- accession: 0001664710-25-000008
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2025-01-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471025000008/0001664710-25-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471025000008/kros-20250116.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-25-000008
- JSON: https://secwatch.observer/filing/0001664710-25-000008.json
- Plain text: https://secwatch.observer/filing/0001664710-25-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.